A Teenager with Hypogammaglobulinemia and New Pulmonary Nodules



Sahar Al Baroudi, L.E. Ortiz, B. Kurdi, K.E. Powers, J.M. Collaco, S.A. McGrath-Morrow Johns Hopkins Medical Institutions - Baltimore, MD/US

Case presentation: Sahar Al Baroudi, MD Discussant: Dennis C. Stokes, MD, MPH



- An 18 year old female with a past medical history of hypogammaglobulinemia and protein-losing enteropathy, who was admitted for abdominal pain and hematochezia
- One week into her hospitalization, she developed acute respiratory distress requiring up to 1.5 lpm nasal cannula of supplemental oxygen. Pulmonary service was consulted



- Past Medical History:
 - Previously healthy until 15 years old
 - Protein-losing enteropathy (diagnosed March 2015)
 - Benign brain lesion (diagnosed February 2016)
 - Hypogammaglobulinemia (diagnosed March 2016)
 - Other diagnoses: autoimmune hepatitis, iron deficiency anemia, hypothyroidism, anxiety



- Family History:
 - Negative for asthma or other lung diseases
- Social History:
 - Left college due to illness
- Review of Systems:
 - Developed dyspnea with activity during this admission
- Allergies:
 - Amoxicillin rash

- Medications at time of consult:
 - Hypogammaglobulinemia
 - Immune Globulin (IVIG) 15g IV on Tues and Thurs
 - Hypothyroidism
 - Levothyroxine
 - Vitamin D Deficiency
 - Cholecalciferol
 - Anxiety
 - Sertraline

- Protein-losing enteropathy
 - Azathioprine
 - Prednisone 10 mg daily
 - Octreotide
 - Total parenteral nutrition (TPN)
- Nausea
 - Promethazine
 - Dronabinol
 - Ondansetron PRN
- Abdominal pain
 - Clonidine patch
 - Hydromorphone





- Physical Exam:
 - T 37C, HR 122, BP 107/65, RR 26, O2 Sat 94% on 1.5 LPM NC
 - General: No acute distress
 - Lungs: (+) Tachypnea. No grunting, flaring, or retractions were present. Auscultation revealed clear breath sounds. (+) Bibasilar diminished aeration
 - Heart: Regular rate and rhythm, normal S1/S2, no murmurs
 - Abdomen: Normoactive bowel sounds. (+) Diffusely
 tender. Soft, non-distended
 - Extremities: No clubbing, cyanosis or edema.
 - Neurology: Unremarkable



- Most recent laboratory studies at time of consult:
 - VBG: pH 7.35/ pCO2 48/ bicarb 25
 - CBC: WBC 9.4/HgB 6.2/Hct 29.9/Plts 398k
 - CMP: Na 138/ K 3.7/ CI 102/ Bicarb 21/ BUN 12/ Cr
 0.5/ Gluc 86/ Prot 4.7/ Alb 2.4
 - IgG 1250 (N), pre-transfusion IgG 355 (L)
 - IgA 25 (L), IgM 16 (L)
 - CD3+ 87.6% (H), CD4+ 55% (H), Absolute CD4+ 513
 (L), CD8+ 32.4% (N), CD4/CD8 1.7



• Chest radiograph one week after admission:



Audience response question 1

- Next step?
 - 1) Bronchoscopy with BAL
 - 2) Bronchoscopy with transbronchial lung biopsy
 - 3) Open lung biopsy
 - 4) Empiric broad spectrum antimicrobial coverage and wait to see if she improves
 - 5) Chest CT scan


Audience response question 1

- Next step?
 - 1) Bronchoscopy with BAL
 - 2) Bronchoscopy with transbronchial lung biopsy
 - 3) Open lung biopsy
 - 4) Empiric broad spectrum antimicrobial coverage
 - 5) Chest CT scan



• Chest CT scan with/without contrast





Bilateral nodular consolidations and patchy ground-glass opacities

Case discussion



• Dr. Stokes: diagnostic approach

Diagnostic approach to the immunocompromised host with an unknown pulmonary process: "pneumopathy X"

Dennis C. Stokes MD MPH St. Jude Children's Research Hospital Professor of Pediatrics (Pulmonology)

University of Tennessee Health Science Center





Dr. Helen Taussig: Final Meeting Harriet Lane Home Amphitheatre 1974



My approach

- Team sport (Radiology, ID, A/I, Surgery)
- Likely diagnoses based on host immune defect
- Review radiology
 - Special thanks to Dr. Dick Heller
- Make sure the non-invasive "t's" are crossed
 - Sputum, including induced sputum
 - Rapid antigen testing, blood work
- Invasive diagnostic studies
 - Bronchoscopy
 - Lung biopsy







Differential dx based on underlying host defect

- Primary immunodeficiency
 - CGD: Aspergillus spp, Staph, B. cepacia
 - CVID: preRx: encapsulated organisms PostAbRx: Staph, fungi, viral
- Secondary/acquired immunodeficiency
 - Neutropenia: H. flu, S. pneumoniae, Staph, Klebsiella
 - Immunosuppressive therapies, e.g. cancer therapies
 - Bacterial: Staph
 - Fungal: Aspergillus spp., Mucor spp, Histoplasmosis
 - Viral: CMV, PCP, VZV, HSV, RSV, hMPV





Differential dx based on underlying host defect

- HSCT
 - Early (<30 days): Pseudomonas other bacterial, Candida spp
 - Late (>30 days): Staph, Aspergillus spp, CMV, toxo, PCP, EBV, adenovirus, RSV
 - >100 days: Encapsulated Gram pos, VZV
- Post HSCT non-infectious complications
 - Edema
 - VOD
 - DAH
 - Idiopathic pneumonia
 - GVHD
 - Interstitial lung disease
 - PTLD
 - OB
 - COP





- Limited specificity to radiographic patterns
- Airspace consolidation
 - Hospital/community acquired pneumonias
 - Fungal pneumonia
 - Aspiration
 - Idiopathic pneumonia syndrome
 - Tb/atypical Tb
 - DAH
 - ARDS
 - Pulmonary edema
 - TRALI: transfusion related acute lung injury





- Nodular lesions
- Discrete
 - Fungal infection
 - Nocardia
 - Metastatic calcifications
 - PTLD: post transplant lymphoproliferative disease
 - Malignancy
 - Septic emboli
- Tree-in-bud pattern
 - Viral pneumonia
 - Bacterial pneumonia
 - BOS





- Ground glass opacities
 - Pulmonary edema
 - TRALI
 - ARDS
 - DAH
 - CMV
 - PCP
 - Viral: CMV, Respiratory (RSV, hMPV, parainfluenza, adenovirus)
 - Drug injury



Radiology: CT versus plain radiography

- CT more sensitive to extent of lung change
- May show secondary findings: early cavitary change, pleural effusions, splenic fungal lesions
- Helps plan invasive diagnostic studies: bronchoscopy/BAL, TBB, needle aspiration biopsy
- In suspected BOS, HRCT with inspiratory/expiratory view may be sufficient to avoid open lung biopsy



Non-invasive testing

- Sputum: induced, or after intubation
- Rapid viral panels: RSV, influenza, parainfluenza, Chlamydia
- Serum galactomanan for Aspergillus
- Urinary antigen, serum antibodies for Histoplasmosis
- Genetic probes: P. jirovecii, Legionella, Mycoplasma pneumoniae





• Indications:

- Failure to clear with appropriate empiric therapy
- Suspicion of endobronchial obstruction (infection, tumor)
- Recurrent pneumonia in lobe or segment
- Suspicion of opportunistic infection (e.g. *P. jirovecii*)



Bronchoscopy

- Broncho-alveolar lavage
- Bronchoscopic biopsy techniques
 - Mucosal biopsy
 - "Blind" transbronchial biopsy
 - "Guided" biopsy: EBUS, CT-guided/navigational methods
- Limitations
 - Limited availability of "guided" techniques in pediatrics
 - Potential application to pulmonary nodular disease
 - ? Less risk than IR CT guided needle aspiration biopsy
- What is the value of a "negative" bronchoscopy
 - Narrowing/discontinuing antimicrobial coverage
 - Fungal pneumonias: yield lowest when done early
 - May be improved by galactomannan detection BAL





- IR: CT-guided needle aspiration biopsy
 - Risk of hemorrhage, pneumothorax, non-diagnostic biopsy
- Open lung biopsy
 - Thoracotomy
 - Thoracoscopic biopsy (VATS)

• NOW BACK TO THE CASE....







- She subsequently developed a fever, and was treated for presumed bacterial pneumonia with a 14 day course of cefepime, and was started on prophylactic pentamidine
- However, her fever did not improve on antibiotics, and an inflammatory process was suspected



- Bronchoscopy with BAL and other infectious work-up were negative
- Nodule biopsy via VATS with RUL wedge resection showed necrotic and chronic inflammation pathology







- Hospital course after lung biopsy:
 - Respiratory
 - Supplemental oxygen requirement increased to 4 LPM via nasal cannula
 - Gl
 - Stool output improved; were able to decrease dose of IVIG
 - Immunology
 - IgG levels remained stable on smaller dose of IVIG
 - ID
 - Fever resolved; no new growth from bronchoscopy alveolar lavage
 - Neurologic
 - Mental status intact, brain lesion unchanged on repeat imaging
 - Endocrine
 - Stable on levothyroxine

- Most common primary immunodeficiency
 - Prevalence: 1:25,000-1:30,000
- Definition (ESID, 2014):
 - Age > 4
- At least one:
 - Increased susceptibility to infection
 - Autoimmune disease
 - Granulomatous disease
 - Unexplained polyclonal lymphoproliferation
 - Affected family member with Ab deficiency
- AND
 - Marked decrease IgG, IgA (with or w/o low IgM)
 - Poor functional Ab response





- AND
 - Secondary causes of hypogammaglobulinemia ruled out
- AND
 - no evidence of profound T-cell deficiency



• Chronic and recurrent infections in 32 children with CVID

Bronchitis	88%
Pneumonia	78%
• Sinusitis	78%
• OM	69%
 Fungal infections (including skin) 	47%
 GI infections 	34%
 Skin infections 	22%
 Parasites 	16%
 Conjunctivitis 	9%
 Oral infections 	9%

Urschel, S et al J. Pediatr 2009;154:888



Noninfectious pulmonary disease

- More common in adolescence, young adulthood
- "Granulomatous-lymphocytic interstitial lung disease"
 - Granulomatous lung disease
 - Lymphocytic interstitial lung disease (LIP)
 - Follicular bronchiolitis
 - Lymphoid hypeplasia

• Risk of progression to B-cell lymphomas

Ambruso, DR, Johnston, RB Primary immunodeficincy (Kendig and Chernick's Disorders of the Respiratory Tract in Children, 8th ed, 2012



Emerging genetic basis of CVID

- Multiple genetic disorders associated with the CVID phenotype
- Majority of familial cases appear autosomal dominant
 - NFKB2
 - CD19
 - TACI
 - ICOS
 - PIK3CD gain of function mutations
 - CTLA-4 loss of function mutations
- LATAIE: similar phenotype but autosomal recessive inheritance
 - Biallelic mutations in LRPA gene
 - "<u>LRBA deficiency with autoantibodies</u>, regulatory <u>T</u> (Treg) cell defects, <u>autoimmune infiltration</u>, and <u>enteropathy</u>"

Lo, B et al Blood 2016;128:1037



Audience response question 2

- What diagnostic test would you do next?
 - 1) Repeat lung biopsy at a more pathologic area
 - 2) Additional targeted immunologic testing
 - 3) Whole exome sequencing with targeted genetic testing
 - 4) Stop antibiotics and repeat broncho-alveolar lavage off antibiotics

Audience response question 2

- What diagnostic test would you do next?
 - 1) Repeat lung biopsy at a more pathologic area
 - 2) Additional targeted immunologic testing
 - 3) Whole exome sequencing with targeted genetic testing
 - 4) Repeat bronchoscopy alveolar lavage off antibiotics



 She had whole exome sequencing that revealed a missense mutation (c.140 T>C, p.Leu47Pro) in CTLA-4 gene. This was confirmed by targeted genetic sequencing

Case discussion




• CTLA-4 haploinsufficiency as a new model of immunodeficiency and autoimmunity

Discussion



 Cytotoxic T-Lymphocyte associated antigen 4 (CTLA-4) sends an inhibitory signal to T-cells




NIH: The National Center for Biotechnology Information, 2016; Orencia, 2017

Discussion



- CTLA-4: cytotoxic T lymphocyte antigen 4: critical "checkpoint" of immune response
- Ctla4 knockout mice: lethal multiorgan lymphocytic infiltration
- <u>CHAI</u>: syndrome of <u>CTLA-4</u> <u>haploinsufficiency</u> with <u>autoimmune infiltration</u>
 - Heterozygous loss of function mutations associated with lymphocytic organ infiltrations including lung



Lo, B et al Blood 2016;128:1037


Figure 1. CHAI and LATAIE disease phenotype and mechanism. (A) Clinical features of CHAI and LATAIE disease. (B) Schematic of the *CTLA4* exons showing the mutations in CHAI patients. TM, transmembrane domain. A schematic displaying *LRBA* mutations causing LATAIE can be found in Lo et al, ¹² Alkhairy et al, ¹⁷ and Gámez-Díaz et al.¹⁸ (C) Model depicting the function of CTLA-4 and its regulation by LRBA.





Case presentation: treatment

• Abatacept contains Fc region of immunoglobulin attached to the CTLA-4. This can replace the CTLA-4 in providing an inhibitory signal for T-cell activation



Lo et al, 2015; Orencia, 2017



Case presentation: later course

- She was treated with abatacept and sirolimus for CTLA-4 deficiency for additional immunosuppression. She was continued on IVIG due to hypogammaglobulinemia
- Her symptoms improved, and she was discharged home on supplemental oxygen 2 LPM via nasal cannula


Case presentation

• Serial chest CT scans



One month prior to abatacept & sirolimus





Two months post abatacept & sirolimus




Case presentation: outpatient follow-up

- Ambulating better on room air
- Shortness of breath with walking longer than 30 minutes or going up stairs
- Albuterol used once over the past month



Pulmonary function tests



JOHNS HOPKINS

Case presentation: outpatient follow-up

- Immunology:
 - Continued on abatacept, sirolimus, and IVIG. Planning for bone marrow transplant
- ID:
 - Mycobacterium avium-intracellulare treatment: Started on ethambutol, azithromycin, and rifampin for positive sputum culture
 - Pneumocystis prophylaxis: Switched from pentamidine to sulfamethoxazole-trimethoprim
- GI:
 - Continued on TPN

Questions?

References



- Buchbinder, Elizabeth, and F. Stephen Hodi. "Cytotoxic T Lymphocyte Antigen-4 and Immune Checkpoint Blockade." Journal of Clinical Investigation 125.9 (2015): 3377-383. Web. 3 May 2017. https://www.jci.org/articles/view/80012/pdf>.
- "CTLA4 Cytotoxic T-lymphocyte Associated Protein 4 [Homo Sapiens (human)] Gene -NCBI." National Center for Biotechnology Information. U.S. National Library of Medicine, n.d. Web. 26 Oct. 2016. https://www.ncbi.nlm.nih.gov/gene/1493>.
- "CTLA4 Deficiency | NIH: National Institute of Allergy and Infectious Diseases." U.S National Library of Medicine. U.S. National Library of Medicine, n.d. Web. 27 Oct. 2016.
 https://www.niaid.nih.gov/diseases-conditions/ctla4-deficiency.
- Lo, B., J. M. Fritz, H. C. Su, G. Uzel, M. B. Jordan, and M. J. Lenardo. "CHAI and LATAIE: New Genetic Diseases of CTLA-4 Checkpoint Insufficiency." Blood 128.8 (2016): 1037-042. Web. 1 May 2017. http://www.bloodjournal.org/content/128/8/1037?sso-checked=true>.
- Lo, Bernice, Kejian Zhang, Wei Lu, et al. "Patients with LRBA Deficiency Show CTLA4 Loss and Immune Dysregulation Responsive to Abatacept Therapy." Science 349.6246 (2015): 436-40. 24 July 2015. Web. 25 Oct. 2016. http://science.sciencemag.org/highwire/citation/633231/reference-manager>.
- "ORENCIA." Role of T Cells in Rheumatoid Arthritis. Bristol-Myers Squibb Company, Feb. 2017. Web. 07 May 2017. http://www.orenciahcp.com/role-of-t-cells-in-rheumatoid-arthritis-.
- Pandit, C, Hsu, P, van Asperen, P et al. Respiratory manifestations and management in children with common variable immunodeficiency Paediatr Resp Rev 2016;19:56-61.
- Urshel, S, Kayikci, L, Wintergerst, U, et al. Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation. J. Pediatr 2009:154:888-94.